stock here: well this is a new one, I knew there were long term effects, but the FDA “lady” who was covering up these Adverse Events, quit her job when Trump came in, and went immediately to work for Pfizer.
Read the whole thing at the substack. We need to stop the abuse of our nations children. I also wonder if the URF, under reporting factor, is similar to VAERS at 42 to 100? See below A-Eye provided good info.
This substack is Malone News, which is different that the oddly named “Who is Robert Malone”
Over the last two decades, around 70,000 reports of harm from puberty-blocking medications were submitted to the FDA’s Adverse Event Reporting Database (AERS). Yet the FDA “Drug Risk Monitoring Board” report never mentioned any of these submissions.
In addition to AERS, published data shows that cross-sex hormones and puberty blockers are correlated with dramatically increased (7-fold) risks of stroke, heart attack, and blood clots along with additional studies also showing serious life-threatening adverse events and other permanent, physiologically devastating consequences.
————————– Amazingly A-Eye gave me a decent, believable, report on the URF. I guess it hasn’t been trained to lie about this issue yet.
The FDA’s Adverse Event Reporting System (AERS), now part of the FDA’s FAERS (FDA Adverse Event Reporting System), is known to suffer from significant underreporting. While estimates vary widely depending on the type of drug, severity of the adverse event, and other factors, studies have generally found that:
Only a small fraction of adverse events are reported:
Many estimates suggest that as few as 1–10% of actual adverse events are captured in the system. This means that for every event reported, there could be 10 or more that go unrecorded.
Severity matters:
More severe or unusual events are more likely to be reported compared to common or less serious ones, which can further skew the data.
Inherent limitations of passive surveillance:
Because AERS relies on voluntary reporting by healthcare providers, patients, and manufacturers, underreporting is an expected limitation of the system.
In short, while the exact underreporting factor isn’t precisely known, the consensus in the literature is that the actual number of adverse events could be substantially higher—potentially 10–50 times the reported figures—highlighting the need for cautious interpretation of AERS data.
————————————————